Outcomes of neutropenic hemato-oncological patients with viridans group streptococci (VGS) bloodstream infection based on penicillin susceptibility
Authors:
- 11 December 2022
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 42 (2) , 177-182
Abstract
Viridans group streptococci (VGS) bloodstream infection (BSI) in neutropenic patients can be a severe complication. A higher prevalence of vancomycin use has been reported due to reduced susceptibility to penicillin. We aimed to assess the impact on mortality of both penicillin minimal inhibitory concentration (MIC) and the use of vancomycin. We conducted a retrospective multicenter study including consecutive neutropenic patients with VGS BSI between 2007 and 2019. Univariable and multivariable analyses were conducted to evaluate risk factors for mortality, including penicillin susceptibility as an independent variable. Non-susceptibility to penicillin was defined as MIC ≥ 0.25. We included 125 neutropenic patients with VGS BSI. Mean age was 53 years and ~ 50% were women. Overall, 30-day mortality rate was 25/125 (20%), and 41 patients (33%) had a VGS isolate non-susceptible to penicillin. In univariable analysis, no significant association was demonstrated between penicillin non-susceptibility and mortality (9/25, 26% vs. 32/100, 32%, p = 0.81). Among patients with a non-susceptible strain, the use of vancomycin was not significantly associated with mortality (empirical, p = 0.103, or definitive therapy, p = 0.491). Factors significantly associated with increased mortality in multivariable analysis included functional status (ECOG > 1, adjusted odds ratio [aOR] 12.53, 95% CI 3.64–43.14; p < 0.0001); allogeneic transplantation (aOR 6.33, 95% CI 1.96–20.46; p = 0.002); and co-pathogen in blood cultures (aOR 3.99, 95% CI 1.34–11.89; p = 0.013). Among neutropenic hemato-oncological patients with VGS BSI, penicillin non-susceptibility and the use of vancomycin were not associated with mortality. Thus, vancomycin should not be used routinely as empirical therapy in neutropenic patients with suspected VGS BSI.Keywords
This publication has 17 references indexed in Scilit:
- Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Can Accurately Differentiate Aeromonas dhakensis from A. hydrophila, A. caviae, and A. veroniiJournal of Clinical Microbiology, 2014
- Editorial Commentary: Viridans Group Streptococci in Febrile Neutropenic Cancer Patients: What Should We Fear?Clinical Infectious Diseases, 2014
- Development and Validation of a Clinical Model to Predict the Presence of β-Lactam Resistance in Viridans Group Streptococci Causing Bacteremia in Neutropenic Cancer PatientsClinical Infectious Diseases, 2014
- Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer2014
- Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia in children with febrile neutropeniaInfection, 2013
- Acute Respiratory Distress SyndromeJAMA, 2012
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Epidemiology and Risk Factors for Gram‐Positive Coccal Infections in Neutropenia: Toward a More Targeted Antibiotic StrategyClinical Infectious Diseases, 2003
- Viridans Streptococcal Bacteraemia Due to Penicillin-Resistant and Penicillin-Sensitive Streptococci: Analysis of Risk Factors and Outcome in 60 Patients from a Single Cancer Centre Before and After Penicillin is Used for ProphylaxisScandinavian Journal of Infectious Diseases, 1997
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992